Ben Seale, MD
Endocrinology, Diabetes & Metabolism · Jackson, MSNPI 1720129950
Payments from drug & device makers
Across 1,838 payments — averaging $338.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$337K
- Novo Nordisk$177K
- Sanofi-aventis U.S. LLC$38K
- AstraZeneca$20K
- Johnson & Johnson$18K
- AbbVie$17K
- plus $15K from 54 others
What the payments were for
- Consulting fees$3,2501%
- Speaking & faculty fees$556,98589%
- Travel & lodging$32,3245%
- Food & beverage$30,2045%
- Education$1020%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$157,678
- TRULICITY$135,097
- Ozempic$88,340
- RYBELSUS$82,094
- SOLIQUA 100/33$22,869
- FARXIGA$19,152
- TOUJEO$17,778
- INVOKANA$17,374
- Synthroid$16,925
- WATCHMAN Access System$867
- JARDIANCE$363
- Korlym$245
- Wegovy$244
- Kerendia$233
- ISTURISA$167
- SIGNIFOR LAR$167
- EVENITY$125
- MINIMED 780G$119
- Levemir$114
- NovoLog$114
How this compares
$622,864 in reported general payments places this provider in the 90th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
See all endocrinology, diabetes & metabolism providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 12 | $518,111 |
| OzempicSemaglutide | 248 | $311,072 |
| MounjaroTirzepatide | 257 | $304,356 |
| Tresiba Flextouch U-200Insulin Degludec | 120 | $175,036 |
| TrulicityDulaglutide | 137 | $162,484 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 146 | $151,833 |
| JardianceEmpagliflozin | 104 | $110,941 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 46 | $88,829 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $84,172 |
| Xigduo XrDapaglifloz Propaned/Metformin | 94 | $80,598 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 61 | $67,886 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 58 | $65,758 |
| Tresiba Flextouch U-100Insulin Degludec | 94 | $60,474 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $59,406 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 42 | $48,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $1,192 | $518,11112 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $336,967 | $470,817405 claims |
| Novo NordiskOzempic, Fiasp, Rybelsus, Xultophy 100-3.6, Novolog | $177,195 | $424,981362 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Glyxambi, Tradjenta | $1,513 | $266,382246 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $38,411 | $151,833146 claims |
| MerckJanuvia, Janumet Xr | $561 | $50,78350 claims |
| AbbVieSynthroid | $17,322 | $31,463344 claims |
| AstraZenecaFarxiga | $20,449 | $22,94427 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $184 | $8,136820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 48 endocrinology, diabetes & metabolism providers in Mississippi.
Other endocrinology, diabetes & metabolism in Jackson
- Honey EastJackson$904K
- Eric DyessJackson$885K
- Amanda SchieferJackson$204K
- John SistrunkJackson$133K
- Vishnu GarlaJackson$88K
- Raymond GrenfellJackson$16K
- Vanessa SandiferJackson$14K
- John KnightJackson$9K
- Jana PhillipsJackson$8K
- Robert EvansJackson$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.